AI
Friday, August 19, 2016 8:15:53 PM
[color=red][/color]Gabor and Chas
Guess what meds change .
Since ANCHOR was run , don't be surprised if more CAD patients were moved onto Lipitor once it went generic ( Gabor will know the date...
Data clearly shows Lipitor better then Simavastatin .
Suggest you both read up on Dr Christie Ballantynes ( Anchor trial ) views on LDL , HsCrp etc .
For instance
http://www.medscape.com/viewarticle/714693_5
Specifically ...from the link
. Group 4 individuals numerically had the highest average 10-year–predicted CHD risk and the highest MACE rates of the 4 groups, confirming prior analyses from primary prevention trials which showed that the highest incidence of CVD occurred in "high" LDL-C and "high" hs-CRP groups.[14,15] ( thought I'd do a "Gabor "..
So figure this in when you do your calc's with R-IT vs JELIS
thx
Kiwi
Guess what meds change .
Since ANCHOR was run , don't be surprised if more CAD patients were moved onto Lipitor once it went generic ( Gabor will know the date...
Data clearly shows Lipitor better then Simavastatin .
Suggest you both read up on Dr Christie Ballantynes ( Anchor trial ) views on LDL , HsCrp etc .
For instance
http://www.medscape.com/viewarticle/714693_5
Specifically ...from the link
. Group 4 individuals numerically had the highest average 10-year–predicted CHD risk and the highest MACE rates of the 4 groups, confirming prior analyses from primary prevention trials which showed that the highest incidence of CVD occurred in "high" LDL-C and "high" hs-CRP groups.[14,15] ( thought I'd do a "Gabor "..
So figure this in when you do your calc's with R-IT vs JELIS
thx
Kiwi
